8QQ.F Stock Analysis
8Q
Uncovered
Abcellera Biologics Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. The company is headquartered in Vancouver, British Columbia and currently employs 495 full-time employees. The company went IPO on 2020-12-11. The Company’s full-stack, AI-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. The company rebuilds the platform that integrates modern technologies from engineering, microfluidics, single-cell analysis, high-throughput genomics, machine learning, and hyper-scale data science. The firm partners with drug developers of all sizes, from large cap pharmaceutical to small biotechnology companies, enabling them to tackle the toughest problems in drug development.